These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 32805254)

  • 41. Dexamethasone enhances the antitumor efficacy of Gemcitabine by glucocorticoid receptor signaling.
    Gong JH; Zheng YB; Zhang MR; Wang YX; Yang SQ; Wang RH; Miao QF; Liu XJ; Zhen YS
    Cancer Biol Ther; 2020 Apr; 21(4):332-343. PubMed ID: 31906826
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study.
    Perng RP; Chen YM; Ming-Liu J; Tsai CM; Lin WC; Yang KY; Whang-Peng J
    J Clin Oncol; 1997 May; 15(5):2097-102. PubMed ID: 9164223
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer.
    De Pas T; de Braud F; Danesi R; Sessa C; Catania C; Curigliano G; Fogli S; del Tacca M; Zampino G; Sbanotto A; Rocca A; Cinieri S; Marrocco E; Milani A; Goldhirsch A
    Ann Oncol; 2000 Jul; 11(7):821-7. PubMed ID: 10997809
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Curcumin enhances drug sensitivity of gemcitabine-resistant lung cancer cells and inhibits metastasis.
    Dong Z; Feng Q; Zhang H; Liu Q; Gong J
    Pharmazie; 2021 Nov; 76(11):538-543. PubMed ID: 34782038
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a phase I study.
    Frasci G; Panza N; Comella P; Nicolella GP; Natale M; Pacilio C; Gravina A; Caputi V; Botti G; Comella G
    Ann Oncol; 1997 Oct; 8(10):1045-8. PubMed ID: 9402180
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Triplex-forming oligonucleotides targeting c-MYC potentiate the anti-tumor activity of gemcitabine in a mouse model of human cancer.
    Boulware SB; Christensen LA; Thames H; Coghlan L; Vasquez KM; Finch RA
    Mol Carcinog; 2014 Sep; 53(9):744-52. PubMed ID: 23681918
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression of hENTl and ERCC1 genes in tumor tissues non-small cell lung cancer.
    Wu JJ; Jiao SC
    Asian Pac J Trop Med; 2013 Nov; 6(11):908-11. PubMed ID: 24083589
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
    Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gambogic acid-induced autophagy in nonsmall cell lung cancer NCI-H441 cells through a reactive oxygen species pathway.
    Ye L; Zhou J; Zhao W; Jiao P; Ren G; Wang S
    J Cancer Res Ther; 2018 Dec; 14(Supplement):S942-S947. PubMed ID: 30539827
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gemcitabine potentiates anti-tumor effect of resveratrol on pancreatic cancer via down-regulation of VEGF-B.
    Yang Y; Tian W; Yang L; Zhang Q; Zhu M; Liu Y; Li J; Yang L; Liu J; Shen Y; Qi Z
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):93-103. PubMed ID: 32897433
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer: a randomized phase II SICOG trial.
    Comella P; Chiuri VE; De Cataldis G; Filippelli G; Maiorino L; Vessia G; Cioffi R; Mancarella S; Putzu C; Greco E; Palmeri L; Costanzo R; Avallone A; Franco L
    Lung Cancer; 2010 Apr; 68(1):94-8. PubMed ID: 19545929
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
    Davies AM; Ruel C; Lara PN; Lau DH; Gumerlock PH; Bold R; Shibata S; Lenz HJ; Schenkein DP; Gandara DR
    J Thorac Oncol; 2008 Jan; 3(1):68-74. PubMed ID: 18166843
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecularly targeted gemcitabine-loaded nanoparticulate system towards the treatment of EGFR overexpressing lung cancer.
    Wang XB; Zhou HY
    Biomed Pharmacother; 2015 Mar; 70():123-8. PubMed ID: 25776490
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma.
    Tonkinson JL; Worzalla JF; Teng CH; Mendelsohn LG
    Cancer Res; 1999 Aug; 59(15):3671-6. PubMed ID: 10446980
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of Gemcitabine Loaded PLGA/Lecithin Nanoparticles for Non-Small Cell Lung Cancer Therapy.
    Esim O; Ozkan CK; Sarper M; Savaser A; Ozkan Y
    Curr Drug Deliv; 2020; 17(7):622-628. PubMed ID: 32394837
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
    Higuchi T; Kawaguchi K; Miyake K; Oshiro H; Zhang Z; Razmjooei S; Wangsiricharoen S; Igarashi K; Yamamoto N; Hayashi K; Kimura H; Miwa S; Nelson SD; Dry SM; Li Y; Chawla SP; Eilber FC; Singh SR; Tsuchiya H; Hoffman RM
    Biomed Pharmacother; 2019 Mar; 111():835-840. PubMed ID: 30616082
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Development and characterization of a gemcitabine-resistant variant of human lung adenocarcinoma cell line A549].
    Dong M; Lin C; Feng FY; Zhang XY; Fu M; Liang X; Lu HY; Zha YY; Wu M
    Ai Zheng; 2004 Jun; 23(6):667-71. PubMed ID: 15191667
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine.
    Vansteenkiste J; Vandebroek J; Nackaerts K; Dooms C; Galdermans D; Bosquée L; Delobbe A; Deschepper K; Van Kerckhoven W; Vandeurzen K; Deman R; D'Odemont JP; Siemons L; Van den Brande P; Dams N;
    Lung Cancer; 2003 May; 40(2):191-9. PubMed ID: 12711121
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
    Vendetti FP; Lau A; Schamus S; Conrads TP; O'Connor MJ; Bakkenist CJ
    Oncotarget; 2015 Dec; 6(42):44289-305. PubMed ID: 26517239
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Temperature-sensitive magnetic drug carriers for concurrent gemcitabine chemohyperthermia.
    Kim DH; Guo Y; Zhang Z; Procissi D; Nicolai J; Omary RA; Larson AC
    Adv Healthc Mater; 2014 May; 3(5):714-24. PubMed ID: 24574255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.